ABSTRACT

TanoMed
Prof. Ronit Satchi-Fainaro, Co-Founder and CSO

- **Investment Rational**

TanoMed technology is a disruptive dendritic cell (DC)-targeted Nano-ImmunoModulator (TNM) that trains host immunity to destroy CEACAM5-positive cancers. CEACAM5, a metastatic driver correlated to poor prognosis in several types of cancer, mainly in gastrointestinal (GI) cancers representing 35% of all cancer-related deaths. TNM platform induced a safe and robust pre-clinical efficacy in pancreatic, colorectal and breast cancers, melanoma, and glioblastoma.

- **Business Strategy**

TanoMed selected TNM-101 (polymeric-nanoparticle incorporating CEACAM5 epitopes and immunoregulator siRNA) as the first indication and is building a strong pipeline against other cancer types and infectious diseases. An international patent application was filed by Ramot/Tel Aviv University and licensed to TanoMed, that will file for additional patents related to new TNM formulations, API and adjuvants, including their applications thereof.

- **Core Technology**

TNM is a unique off-the-shelf cost-effective multifunctional mannose-grafted nanoplatform suitable to co-deliver to DC short and long peptides and toll-like receptor (TLR) ligand by the same nanoparticle. This is a key step to overcome T-cell exhaustion, improve sensitivity and long-term memory tumor recognition, while overcoming the need for intratumoral administration of these clinically-relevant immunoregulators. TanoMed's valuation is currently $20M.

- **Product Profile/Pipeline**

TanoMed is seeking a financial investment of $25M from Venture Capital, Pharma companies, as well as from global private investors for Phase 1/2 clinical data on the first TNM product within 36 months. TanoMed White paper application for TNM-101 was approved by the Nanotechnology Characterization Laboratory at the NIH, which will perform pre-clinical safety and toxicology studies free of charge.

- **What's Next?**

TanoMed's strong management team is raising $25M to support i) tech transfer, scale-up and GMP manufacturing by an identified CMO; ii) safety and toxicology studies; iii) R&D activities to develop the pipeline of additional TNM products. Investigational New Drug (IND) Application to be submitted to the FDA by Q4 2023 to reach Phase 1/2 clinical trials in Q1 2024.